Clinical Trial Update: A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

A Phase II study evaluated dasatinib (Sprycel) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-07-18